Skip to main content

Articles

FDA Approvals, Leukemia, Oncology
Oral Onureg First Drug Approved for Adults with AML in Remission
Read More
FDA Approvals
Danyelza Receives FDA Approval for High-Risk Neuroblastoma in the Bone and Bone Marrow
Read More
FDA Approvals
Gavreto, a New RET Inhibitor, Now Approved for Thyroid Cancer with RET Fusions
Read More
Perspectives
The Dirty Dozen Redux
David B. Nash, MD, MBA
Read More
ESMO 2020 Highlights
Olaparib a New Option for Men with Metastatic Prostate Cancer and BRCA Mutation
Phoebe Starr
Read More
ESMO 2020 Highlights
Nivolumab New Standard of Care in Gastroesophageal Cancers as First-Line or Adjuvant Therapy
Phoebe Starr
Read More
Perspectives
Pandemic Posting
David B. Nash, MD, MBA
Read More
Online Only
Perspectives
Politics and Healthcare: Drug Pricing Dynamics Leading Up to the 2020 Election
Gary Branning, MBA; Kathryn Hayes, BA
Read More
Original Research, Practice Management
Economic Implications of Preventing Major Cardiovascular and Limb Events with Rivaroxaban plus Aspirin in Patients with Coronary or Peripheral Artery Disease in the United States
Luis Hernandez, MSc, MPH; Anshul Shah, BS Pharm, MS; Qi Zhao, MD; Dejan Milentijevic, PhD, MBA; Akshay Kharat, PhD
Read More
Original Research, Practice Management
Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States
Michael S. Broder, MD, MSHS; Qiufei Ma, PhD; Tingjian Yan, PhD; Jie Zhang, PhD; Eunice Chang, PhD; David Kuzan, MD; Lamis Eldjerou, MD
Read More
Page 28 of 244
Results 271 - 280 of 2434